Based on the key indicators related to Artelo Biosciences' liquidity, profitability, solvency, and operating efficiency, Artelo Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, Artelo Biosciences' Common Stock Shares Outstanding is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 24.7 M this year, although the value of Retained Earnings are projected to rise to (34.5 M). Key indicators impacting Artelo Biosciences' financial strength include:
Investors should never underestimate Artelo Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Artelo Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Artelo Biosciences.
Net Income
(7.94 Million)
Artelo
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Net Borrowings
Free Cash Flow
Change In Working Capital
Other Non Cash Items
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Sale Purchase Of Stock
Investments
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Stock Based Compensation
Issuance Of Capital Stock
Total Assets
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Cash
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Common Stock
Other Current Liab
Total Current Liabilities
Accounts Payable
Other Assets
Net Receivables
Short Term Investments
Capital Surpluse
Other Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Property Plant Equipment
Non Current Assets Total
Non Currrent Assets Other
Non Current Liabilities Total
Net Invested Capital
Net Working Capital
Property Plant And Equipment Net
Property Plant And Equipment Gross
Capital Stock
Capital Lease Obligations
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Research Development
Net Interest Income
Depreciation And Amortization
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Artelo Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Artelo Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Artelo Biosciences' assets may result in an increase in income on the income statement.
Artelo Biosciences competes with Curis, Salarius Pharmaceuticals, Basilea Pharmaceutica, Ascletis Pharma, and Brii Biosciences. Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Artelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Artelo Biosciences's current stock value. Our valuation model uses many indicators to compare Artelo Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Artelo Biosciences competition to find correlations between indicators driving Artelo Biosciences's intrinsic value. More Info.
Artelo Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Artelo Biosciences' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Artelo Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Artelo Biosciences Systematic Risk
Artelo Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Artelo Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Artelo Biosciences correlated with the market. If Beta is less than 0 Artelo Biosciences generally moves in the opposite direction as compared to the market. If Artelo Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Artelo Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Artelo Biosciences is generally in the same direction as the market. If Beta > 1 Artelo Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Artelo Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Artelo Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Artelo Biosciences growth as a starting point in their analysis.
Artelo Biosciences February 2, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Artelo Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Artelo Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Artelo Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Artelo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Artelo Biosciences's daily price indicators and compare them against related drivers.
When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.87)
Return On Assets
(0.54)
Return On Equity
(0.89)
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.